A multicenter, randomized, double-blind, placebo-controlled, parallel-group,
dose-ranging study to assess the efficacy, safety, and tolerability of escalating transdermal
doses of rotigotine (SPM 962) in subjects with early-stage Parkinson’s disease
Not available
Parkinson's Disease
Phase 2
Currently not available on Sponsor Clinical Study Registry but will be included in the next stepwise expansion of the Registry's scope (by end of Q1 2015).

Analysis and Reporting Dataset is AD not ADaM

Datasets are available in English only

Study is not posted on ClinTrials Gov because it completed prior to registry reporting requirements
July 2014